uniQure NV

uniQure NV's stock surged significantly today, contrasting with the modest rise of the S&P 500. Despite recent challenges, including a decline over the past week and month, the company has achieved impressive one-year returns. However, it faces operational difficulties, including negative EBITDA and debt servicing issues.

uniQure NV, a small-cap biotechnology firm, saw a notable intraday gain today, contrasting with the S&P 500's modest rise. Despite a remarkable annual return, the company faces significant challenges, including operating losses, declining net sales, and a negative EBITDA, raising concerns about its financial stability.

uniQure NV has faced notable volatility, with a significant stock decline today and a staggering drop over the past week. Financial metrics indicate challenges, including negative EBITDA and a low EBIT to interest ratio. The company's recent net sales also fell sharply, raising concerns about its market position.

uniQure NV, a small-cap biotechnology firm, opened with a notable loss, continuing a trend of significant declines over the past month. The company, which has a market capitalization of around USD 956 million and is currently loss-making, exhibits a unique financial structure with a high return on equity.

uniQure NV faced significant stock volatility, dropping 24% in a challenging trading environment. The company reported a 52.71% decline in net sales, contributing to concerns about financial stability, including negative EBITDA and a troubling return on capital employed. Its operational inefficiencies further complicate its market position.

uniQure NV has faced notable volatility, with a significant stock decline today and over the past week. Despite a remarkable year-over-year growth, the company is grappling with financial challenges, including operating losses and a substantial drop in net sales, raising concerns about its financial health.

uniQure NV achieved a new 52-week high of USD 61.79 on October 8, 2025, reflecting a remarkable 1014.68% increase over the past year. Despite being a loss-making small-cap company in the Pharmaceuticals & Biotechnology sector, it has a market capitalization of USD 956 million and notable financial metrics.

uniQure NV, a small-cap biotechnology firm, saw its stock rise significantly on October 7, 2025, amid broader market gains. Despite impressive short-term stock performance, the company faces challenges, including a sharp decline in net sales and negative EBITDA, raising concerns about its financial health and debt servicing capabilities.

uniQure NV has achieved a new 52-week high of USD 55.11, reflecting a remarkable growth of 909.48% in its stock price over the past year. With a market capitalization of USD 956 million, the company demonstrates effective management despite being loss-making and not offering dividends.

uniQure NV achieved a new 52-week high of USD 54.98 on September 25, 2025, reflecting an impressive 878.62% increase over the past year. Despite being a loss-making microcap in the Pharmaceuticals & Biotechnology industry, the company has a market capitalization of USD 956 million and strong financial metrics.

uniQure NV achieved a new 52-week high of USD 51.21 on September 24, 2025, reflecting a significant growth trajectory from its previous low. The company, operating in the Pharmaceuticals & Biotechnology sector, has shown remarkable one-year performance, despite being loss-making and lacking a dividend yield.

uniQure NV faced notable volatility on September 15, 2025, with a significant stock price decline. The company reported a sharp drop in net sales and ongoing operating losses, raising concerns about its financial health. Despite a strong one-year return, its long-term outlook remains uncertain.